World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 5
Page: 279-294

PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD): A COMPREHENSIVE REVIEW

Challa Venku Reddy*, A. Muneeswari, D. Lavanya, K. Teja Sree, P. Deepa, SK. Salma

Department of Pharmacology, Swathi College of Pharmacy, Nellore District, Andhra Pradesh.

Article Received: 31 August 2025 | | ***Article Revised: 21 September 2025*** | | ***Article Accepted: 12 October 2025***

***Corresponding Author: Challa Venku Reddy**
Department of Pharmacology, Swathi College of Pharmacy, Nellore District, Andhra Pradesh.
DOI: https://doi.org/10.5281/zenodo.17368244

How to cite this Article: Challa Venku Reddy, A. Muneeswari, D. Lavanya, K. Teja Sree, P. Deepa, SK. Salma (2025) PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF CHRONIC KIDNEY DISEASE (CKD): A COMPREHENSIVE REVIEW. World Journal of Pharmaceutical Science and Research, 4(5), 279-294. https://doi.org/10.5281/zenodo.17368244

ABSTRACT

Background: Chronic kidney disease (CKD) represents a major and escalating global health challenge, contributing significantly to morbidity, mortality, and healthcare costs across low-, middle-, and high-income countries. Despite established management strategies—such as blood pressure control, glycaemic regulation, and renin–angiotensin system (RAS) blockade—residual renal and cardiovascular risks remain high, and many patients progress to end-stage kidney disease. **Objective:** This review aims to comprehensively synthesize recent pharmacological advances in CKD management, emphasizing novel therapeutic mechanisms, pivotal clinical trial evidence, safety considerations, and implications for clinical practice and guidelines. **Methods:** A narrative review was conducted by examining recent landmark randomized controlled trials, guideline updates (KDIGO, ADA), and systematic reviews indexed in PubMed and related databases, focusing on therapies targeting renal hemodynamics, inflammation, fibrosis, oxidative stress, and metabolic dysregulation. **Results:** Breakthroughs in CKD pharmacotherapy include sodium–glucose cotransporter-2 (SGLT2) inhibitors, which confer robust reno- and cardioprotective effects across diabetic and non-diabetic CKD populations; non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone), which reduce inflammation, fibrosis, and adverse cardiorenal outcomes; and adjunctive therapies such as newer potassium binders (patiromer, sodium zirconium cyclosilicate) enabling sustained RAS blockade. Additional agents—hypoxia-inducible factor prolyl-hydroxylase inhibitors for anemia, glucagon-like peptide-1 receptor agonists, endothelin receptor antagonists, and microbiome-directed interventions—are emerging as important complements to standard care. Evidence supports a paradigm shift toward multimodal, layered pharmacological strategies addressing both traditional and non-traditional pathways. **Conclusion:** Pharmacological management of CKD is rapidly evolving beyond conventional risk-factor control. Integration of SGLT2 inhibitors, selective MRAs, and supportive agents into standard regimens has the potential to substantially improve renal and cardiovascular outcomes. Future priorities include optimizing combination strategies, refining patient selection, and addressing residual risks through therapies targeting inflammation, fibrosis, and the gut–kidney axis.

KEYWORDS: Chronic kidney disease, pharmacotherapy, SGLT2 inhibitors, mineralocorticoid receptor antagonists, renin–angiotensin system, hyperkalemia, inflammation, fibrosis, gut–kidney axis.

1. INTRODUCTION

Chronic kidney disease (CKD) is a major and growing global health problem. Global burden studies show that CKD contributes substantially to morbidity and mortality worldwide and that both prevalence and years lived with disability attributable to impaired kidney function have increased over recent decades, imposing a heavy burden on health systems and economies across low-, middle- and high-income countries.[1]

The socio-economic impact of CKD is multifaceted: affected patients experience a markedly higher risk of cardiovascular disease and premature death, reduced quality of life, and high out-of-pocket and system costs related to progressive kidney failure, dialysis, transplantation and associated comorbidities. These downstream burdens amplify health inequities and strain national health budgets, particularly where access to renal replacement therapy is limited.[1,2]

Traditional management of CKD has focused on risk-factor modification to slow progression and reduce complications. Cornerstones include rigorous blood-pressure control (often with renin–angiotensin system [RAS] blockade), optimal glycemic management in people with diabetes, lipid management and general cardiovascular risk reduction, together with management of complications (anemia, mineral–bone disorder, acidosis, and electrolyte disturbances). RAS inhibitors (ACE inhibitors or ARBs) have been central to reducing proteinuria and delaying progression in many forms of CKD and are widely recommended by contemporary guidelines.[2]

However, conventional therapies have important limitations. Despite best-practice blood-pressure and glycaemic control and use of RAS blockade, many patients continue to experience progressive kidney function decline and high residual cardiovascular risk. Adverse effects such as hyperkalaemia may limit the tolerable intensity of RAS blockade in a substantial subset of patients, reducing the real-world effectiveness of these therapies. In addition, prior to recent trials, effective, broadly applicable disease-modifying treatments that slow progression across diabetic and non-diabetic CKD were lacking.[2,4]

Recent high-quality randomized trials have changed that landscape. Sodium–glucose cotransporter-2 (SGLT2) inhibitors demonstrated robust kidney and cardiovascular protection in patients with CKD regardless of diabetes status (for example, DAPA-CKD), marking a paradigm shift in CKD pharmacotherapy. Similarly, non-steroidal, selective mineralocorticoid-receptor antagonists (for example, finerenone) have shown reductions in CKD progression and cardiovascular events in patients with CKD and type 2 diabetes, though hyperkalaemia remains a concern that requires monitoring and mitigation strategies. Novel agents addressing complications of CKD — such as newer potassium binders (patiromer, sodium zirconium cyclosilicate) that permit continued use of life-saving RAAS/RAS therapies, and hypoxia-inducible factor prolyl-hydroxylase inhibitors for renal anemia (e.g., roxadustat and related agents) — have also expanded the therapeutic armamentarium. These advances are already being incorporated into guideline recommendations and routine practice algorithms.[3,6]

Given this rapid, clinically important evolution, a comprehensive synthesis of newly available and emerging pharmacological strategies is timely. The objective of this review is therefore to summarize and critically appraise recent pharmacological advances in the management of CKD including mechanisms of action, pivotal clinical trial evidence, safety and monitoring issues, guideline implications, and remaining knowledge gaps and to discuss how these developments can be integrated into contemporary clinical practice to optimize renal and cardiovascular outcomes.

2. PATHOPHYSIOLOGICAL BASIS FOR PHARMACOLOGICAL INTERVENTION

1. Hemodynamic factors in CKD progression glomerular hyperfiltration, intrarenal hypertension and raas overactivity

Chronic kidney disease is driven in large part by maladaptive hemodynamic changes at the level of the glomerulus. Early in several CKD etiologies (notably diabetic kidney disease), increased single-nephron glomerular filtration and intraglomerular hypertension (glomerular hyperfiltration) lead to mechanical stress on the glomerular capillary wall, podocyte injury, and mesangial expansion. Persistent elevation of intraglomerular pressure promotes glomerulosclerosis through increased shear stress, filtration barrier disruption and progressive loss of functional nephrons; the remaining nephrons then hyperfilter, perpetuating a vicious cycle. Mechanistically, angiotensin II (via the renin–angiotensin–aldosterone system, RAAS) and sympathetic activation constrict the efferent arteriole, amplify intraglomerular pressure, and stimulate pro-fibrotic and pro-inflammatory pathways (TGF-β, connective tissue growth factor), promoting extracellular matrix deposition and tubulo-interstitial fibrosis. Targeting hemodynamic drivers therefore remains a cornerstone of CKD therapy (e.g., ACE inhibitors/ARBs, mineralocorticoid receptor antagonists, SGLT2 inhibitors which reduce intraglomerular pressure via tubuloglomerular feedback).[7,10]

2. Oxidative stress and inflammation as central, interacting mechanisms

Oxidative stress (excess reactive oxygen species, ROS) and sustained inflammation are central and mutually reinforcing mechanisms in CKD progression. Sources of ROS in the kidney include mitochondrial dysfunction, NADPH oxidase (NOX) isoforms, and increased formation of advanced glycation end products (AGEs). ROS damages cellular proteins, lipids and DNA; it reduces nitric oxide (NO) bioavailability causing endothelial dysfunction and promotes profibrotic signalling. In parallel, CKD is characterized by chronic systemic and intrarenal inflammation elevated levels of CRP, IL-6, TNF-α and adhesion molecules — driven by uremic toxin accumulation, adipose-derived cytokines, recurrent infections, acidosis and dialysis-related exposures. Inflammatory signalling (e.g., NF-κB activation) amplifies oxidative injury and stimulates fibrogenic cascades (TGF-β, myofibroblast activation). Because these pathways contribute to cardiovascular risk, anemia of inflammation, bone-mineral disorders and ESKD, pharmacological strategies that reduce oxidative stress and inflammation (directly or indirectly) can slow CKD progression and improve extra-renal outcomes.[7]

3. Uremic toxins, gut–kidney axis and metabolic mediators

CKD alters the gut microbiome and intestinal barrier function; decreased renal clearance allows gut-derived metabolites (indoxyl sulfate, p-cresyl sulfate, trimethylamine-N-oxide/TMAO) and other uremic toxins to accumulate. These molecules provoke endothelial dysfunction, oxidative stress and pro-inflammatory signalling in both renal and vascular tissues, promoting fibrosis, vascular calcification and atherosclerosis. Dysbiosis and increased intestinal permeability (endotoxemia) further sustain systemic inflammation. Thus, the gut–kidney axis is an important pathophysiological mediator that expands therapeutic targets beyond classic renal hemodynamics to include diet, pre/probiotics, adsorbents (e.g., AST-120 in some trials), bowel-modifying agents and interventions that modulate microbiome composition or toxin production.[8]

4. Crosstalk between kidney disease, cardiovascular system and metabolic syndrome (the cardio-renal-metabolic network)

CKD, cardiovascular disease (CVD) and metabolic dysregulation (insulin resistance, obesity, T2DM) form an interlinked syndrome: each condition increases the risk and worsens outcomes for the others. Shared mechanisms include RAAS and sympathetic overactivity, endothelial dysfunction, systemic inflammation, oxidative stress, dyslipidemia, maladaptive myocardial remodeling, and metabolic endotoxemia. Importantly, therapies that modulate one axis frequently influence the others (for example, SGLT2 inhibitors reduce heart failure events and slow CKD progression independent of glucose lowering; non-steroidal mineralocorticoid receptor antagonists lower cardiorenal events via anti-fibrotic/anti-inflammatory effects). This systemic perspective justifies integrated pharmacologic strategies that simultaneously target hemodynamics, metabolism, inflammation and fibrosis rather than focusing solely on BP or glycemic targets.[9]

5. Importance of targeting pathways beyond blood pressure and glycemic control — therapeutic implications

Although blood pressure control and optimal glycemic management remain foundational, contemporary evidence supports therapies that act on non-traditional pathways to deliver incremental cardiorenal protection

- **SGLT2 inhibitors**: reduce intraglomerular pressure (via tubuloglomerular feedback), natriuresis, interstitial hypoxia, and systemic inflammation; randomized trials show reduced CKD progression and heart failure hospitalization even in non-diabetic populations, indicating mechanisms beyond glycemic lowering.
- **GLP-1 receptor agonists:** improve weight, metabolic profile, and reduce albuminuria / ASCVD risk via metabolic and anti-inflammatory effect.
- **Non-steroidal mineralocorticoid receptor antagonists (e.g., finerenone):** reduce inflammation and fibrosis and have been shown to lower kidney and cardiovascular outcomes in T2D with CKD.
- **Endothelin receptor antagonists, anti-fibrotic agents and selective NOX inhibitors** are under study to directly block fibrogenic and oxidative pathways.
- **Microbiome-directed therapies and uremic toxin-lowering approaches** represent adjunctive strategies to reduce systemic inflammation and vascular toxicity.
- **Immunomodulatory and anti-inflammatory strategies** (targeting IL-1, IL-6, TGF-β, NF-κB or CCR2 pathways) are an active area of translational research their potential to slow CKD progression remains to be fully established in outcome trials.

These advances support a multimodal pharmacological paradigm: combine RAAS blockade and tight risk-factor control with agents that reduce glomerular stress (SGLT2i), block fibrotic/inflammatory signalling (finerenone, investigational agents), and modify systemic drivers (metabolic agents, microbiome therapies). Guideline bodies (ADA, KDIGO) now explicitly recommend layering these treatments for patients with CKD and diabetes, reflecting the shift beyond glycemic/BP endpoints toward integrated cardiorenal protection.[10]

Short synthesis: Translating pathophysiology to pharmacology (clinical research & practice priorities)

1. **Preserve nephron hemodynamics**: continue ACEi/ARB use where indicated; use SGLT2 inhibitors early to reduce hyperfiltration and intrarenal stress.

2. **Target inflammation & oxidative stress:** pursue agents that reduce NOX activity, enhance Nrf2 signaling, or blunt pro-inflammatory cytokines — both repurposed (statins, MRAs) and novel agents require rigorous renal outcome trials.
3. **Address systemic contributors:** treat metabolic dysfunction (GLP-1 RAs, lifestyle), correct dysbiosis/uremic toxin burden (dietary fibre, pre/probiotics, adsorbents) and control cardiovascular risk factors to interrupt cardio-renal-metabolic crosstalk.
4. **Move from single-target to combination strategies:** complementary mechanisms (e.g., RAAS blockade + SGLT2i + finerenone where appropriate) are likely more effective than monotherapy in halting progression; however, careful safety and drug-interaction monitoring is essential.

3. ESTABLISHED PHARMACOLOGICAL THERAPIES

3.1 Renin–Angiotensin–Aldosterone System (RAAS) inhibitors

Mechanism 0f action and overview

ACE inhibitors (ACE-i) and angiotensin-receptor blockers (ARBs) remain foundational therapies for patients with chronic kidney disease (CKD) who have proteinuria. By inhibiting conversion of angiotensin, I to angiotensin II (ACE-i) or blocking the angiotensin II type-1 receptor (ARBs), these agents lower intraglomerular pressure, reduce glomerular hyperfiltration and decrease proteinuria actions that translate into slowed progression of CKD in proteinuric disease. Current guideline consensus supports initiation and titration of an ACE-i or ARB in adults with CKD and moderately-to-severely increased albuminuria as first-line renoprotective therapy, combined with blood-pressure control and other disease-modifying treatments.

Clinical evidence and clinical practice points

Multiple randomized trials and guideline syntheses show that ACE-i/ARBs reduce albuminuria and delay progression to end-stage kidney disease (ESKD) and/or doubling of serum creatinine in proteinuric CKD populations. KDIGO and other major guidance documents recommend ACE-i or ARB use as part of standard care for proteinuric CKD, but advise **against dual RAS blockade** (ACE-i + ARB or direct renin inhibitor combinations) because of an unfavorable risk–benefit profile (increased hyperkalemia, acute kidney injury) without incremental long-term renoprotection. Practical implementation therefore focuses on maximizing a single RAS blocker to tolerated dose, monitoring renal function and potassium closely after initiation or dose changes, and combining RAS blockade with other renoprotective agents (for example, SGLT2 inhibitors in eligible patients) where evidence supports additive benefit.[11]

Mineralocorticoid receptor antagonists (MRAs)

Steroidal MRAs (spironolactone, eplerenone) have long been used for their anti-aldosterone effects (natriuresis, antifibrotic/antiinflammatory actions) and they reduce proteinuria when added to ACE-i/ARB in small trials. However, steroidal MRAs are limited in CKD by dose-dependent adverse effects (spironolactone: endocrine effects such as gynecomastia; both agents: significant risk of hyperkalemia especially as eGFR falls).

A new generation non-steroidal selective MRA, **finerenone**, demonstrated clinically meaningful cardiorenal benefits in large, placebo-controlled phase-3 studies performed on a background of optimized RAAS blockade. In the FIDELIO-DKD program finerenone reduced the risk of a composite renal outcome (sustained ≥40% eGFR decline, kidney failure, or renal death) and reduced key cardiovascular outcomes; FIGARO-DKD showed cardiovascular event reductions in a broader CKD/T2D population. These trials indicate that selective non-steroidal MR antagonism can add

incremental renoprotective and cardioprotective effects beyond maximized ACE-i/ARB therapy in patients with CKD and type-2 diabetes. Nevertheless, finerenone (like other MRAs) increases the incidence of hyperkalemia relative to placebo, so careful potassium monitoring and patient selection remain essential.[12,13]

Limitations: hyperkalemia and incomplete renoprotection

Two practical limitations constrain RAAS-axis therapy in CKD

1. **Hyperkalemia:** a predictable, frequently dose-limiting adverse effect of RAS blockade and of MRAs. Hyperkalemia often leads clinicians to reduce dose or discontinue RAAS inhibitors, thereby forfeiting renoprotective benefit. In many trials and in clinical practice, hyperkalemia is the dominant reason for down-titration. Newer oral potassium binders (patiromer and sodium zirconium cyclosilicate [SZC]) have been shown in randomized trials and meta-analyses to lower serum potassium and enable continuation or up-titration of RAAS pathway therapies in CKD and heart-failure populations; these agents are increasingly used to manage chronic hyperkalemia so patients can remain on guideline-directed RAAS inhibitors when indicated.
2. **Incomplete renoprotection:** despite optimal ACE-i/ARB (and when appropriate, SGLT2 inhibitors and MRAs), residual risk of progression remains for many patients. Mechanisms such as persistent inflammation and fibrosis (partly aldosterone-mediated), metabolic drivers, and non-hemodynamic pathways contribute to this residual risk. The development of agents targeting complementary pathways (e.g., selective MRAs, SGLT2 inhibitors, GLP-1RAs in selected patients) aims to close this gap, but long-term combination strategies require individualized risk–benefit assessment and ongoing safety monitoring (particularly for hyperkalemia, hypotension, and renal function changes).[14]

3.2 BLOOD-PRESSURE–LOWERING AGENTS

Hypertension is both a cause and major accelerator of chronic kidney disease (CKD) progression and cardiovascular morbidity. Optimal BP control slows CKD progression, reduces albuminuria and lowers cardiovascular risk; recent KDIGO guidance recommends a standardized systolic BP target of **<120 mm Hg** for most adults with CKD (non-dialysis) when tolerated.[15]

1. Calcium-channel blockers (CCBs)

CCBs (dihydropyridine and non-dihydropidine) effectively reduce systemic blood pressure in CKD and are widely used as component drugs in combination regimens. Compared with renin–angiotensin system (RAS) blockers, L-type (classic) CCBs (e.g., amlodipine, nifedipine) provide potent BP lowering but generally have **less antiproteinuric effect** than ACE inhibitors/ARBs when used as monotherapy. However, newer subtype-selective agents (L/N-type or L/T-type and certain agents such as cilnidipine/azelnidipine used in some regions) appear to have additional antiproteinuric effects when added to RAAS blockade, and have been associated in meta-analyses with reductions in albuminuria independent of BP lowering. Thus, CCBs are valuable either when RAAS blockade is contraindicated/intolerable or as add-on therapy to obtain BP targets and reduce cardiovascular events.[16,18]

Safety/considerations: edema and reflex tachycardia are more common with some dihydropyridines; non-dihydropyridines (verapamil, diltiazem) may reduce proteinuria but have negative inotropic effects and drug–drug interaction potential (e.g., with calcineurin inhibitors). Use appropriate dose adjustments in advanced CKD mainly for co-administered drugs rather than CCB clearance itself.[17]

2. β-blockers

β-blockers reduce sympathetic overactivity common in CKD and are important for rate control and secondary prevention in patients with cardiac disease. Evidence for primary renoprotective benefit is limited relative to RAS blockade; they are typically **second-line** agents for BP control in CKD unless there are compelling cardiac indications (heart failure with reduced EF, post-MI, arrhythmia). Observational and trial data support cardiovascular benefits of β-blockers in CKD patients with heart failure; head-to-head RCT evidence comparing β-blockers with other antihypertensives for CKD progression is sparse. Choice of β-blocker (lipophilic vs hydrophilic; dialyzable vs non-dialyzable) matters in advanced CKD/ESKD and in dialysis patients.[19,25]

Safety/considerations: may worsen insulin resistance (some agents), mask hypoglycaemia, and require dose individualization in advanced CKD. In dialysis patients consider dialyzability and intradialytic hypotension risk.[19,25]

3. Diuretics

Diuretics (thiazide and loop diuretics) remain mainstays for volume control in CKD. Thiazide-class agents are effective in earlier CKD stages (eGFR >30 mL/min/1.73 m²), whereas loop diuretics are preferred in advanced CKD for volume control. Diuretics can have favourable effects on nocturnal BP and assist RAAS blocker tolerability by mitigating hyperkalaemia risk (when used with caution and monitoring). Recent cohort and comparative analyses suggest differences in long-term renal outcomes between initiation of diuretics and other classes in some populations, but randomized evidence focusing specifically on CKD progression is limited; diuretics are used primarily for fluid control and adjunct BP lowering.[20,21]

Comparative effectiveness (practical summary):

RAAS inhibitors (ACEi/ARB) remain the cornerstone for reducing proteinuria and slowing CKD progression (particularly in proteinuric CKD). When RAAS blockade is central to renoprotection, CCBs and diuretics are commonly used as adjuncts to achieve BP targets recommended by KDIGO. Direct comparative trials show similar BP control across major classes but **superior antiproteinuric effects** of ACEi/ARB versus classic L-type CCBs; certain CCB subtypes (L/N, L/T) may provide additional antiproteinuric benefit as add-ons. Beta-blockers are prioritized where cardiac indications exist. Treatment choice should be individualized according to proteinuria, comorbidity, electrolyte status, and drug tolerability. [15,8,22]

3.3 GLYCAEMIC-CONTROL AGENTS

Glycaemic management in CKD must balance reduction of micro- and macrovascular risk against increased risk of hypoglycaemia from impaired drug clearance and altered insulin metabolism in renal impairment. KDIGO and diabetes guideline panels emphasize individualized HbA1c targets and agent selection based on CKD stage, risk of hypoglycaemia, and non-glycaemic cardiorenal benefits.[22,23]

1. Insulin

Insulin remains the most reliable agent for glycaemic control in advanced CKD and dialysis patients because of potency and predictable glucose-lowering when carefully titrated. Renal impairment reduces insulin clearance and prolongs insulin action — increasing the risk of hypoglycaemia; hence insulin doses usually require **reduction** as eGFR declines and close glucose monitoring is essential. Short-acting and basal insulin regimens should be adjusted

progressively; frequent monitoring and patient education regarding hypoglycaemia are mandatory. When possible, use conservative HbA1c targets in the frail/older CKD population to avoid hypoglycaemic harm.[25]

2. Metformin

Metformin is first-line therapy in type 2 diabetes but requires caution in CKD due to the rare risk of lactic acidosis in severe renal impairment. Regulatory updates now permit metformin initiation only when eGFR is ≥45 mL/min/1.73 m², and continuation with caution down to an eGFR of 30 mL/min/1.73 m² for patients already taking metformin (discontinue if eGFR <30 mL/min/1.73 m²). The 2016 FDA labeling revision and subsequent guideline syntheses recommend assessing eGFR before initiation and periodically thereafter and advise holding metformin around iodinated contrast administration in patients at risk. Thus, metformin remains usable in many CKD patients with appropriate eGFR thresholds and monitoring, but it is **contraindicated** in severe CKD (eGFR <30).[20,21,22]

3. DPP-4 inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors are generally well tolerated in CKD and carry a low risk of hypoglycaemia when used alone or with non-insulin agents. Pharmacokinetic differences matter: linagliptin is primarily hepatically cleared and **does not require dose adjustment** in CKD, making it attractive for advanced CKD; large trials (e.g., CARMELINA) have shown cardiovascular safety and neutral to modest effects on kidney outcomes. Other agents (sitagliptin, saxagliptin, alogliptin) are renally excreted and **require dose reductions** according to eGFR (e.g., sitagliptin dosage lowered for eGFR <45 and further for <30). Use of DPP-4 inhibitors may be preferred in CKD when SGLT2 inhibitors or GLP-1 receptor agonists are contraindicated or not tolerated, but overall cardiorenal advantages differ across classes.[23,24,22]

Limitations in advanced CKD: Several oral hypoglycaemic classes require dose adjustment or are contraindicated in advanced CKD (eGFR <30), and many CV-benefit data are derived primarily from populations with preserved renal function or moderate CKD. Newer classes (SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 RAs) also have important roles in cardiorenal protection but are beyond the scope of this subsection. Glycaemic targets should be individualized, considering competing risks and life expectancy.[22,23]

4. NOVEL PHARMACOLOGICAL ADVANCES IN CKD MANAGEMENT

4.1. Sodium–Glucose Cotransporter-2 (SGLT2) Inhibitors

Mechanism of Action

SGLT2 inhibitors, such as dapagliflozin and empagliflozin, function by inhibiting the SGLT2 protein in the proximal renal tubule, responsible for approximately 90% of glucose reabsorption. This inhibition leads to increased urinary glucose excretion, thereby lowering blood glucose levels. Additionally, SGLT2 inhibition reduces intraglomerular pressure and enhances tubuloglomerular feedback, mechanisms that contribute to kidney protection in CKD patients.[29,30]

Landmark Trials

- **DAPA-CKD Trial**: This pivotal study demonstrated that dapagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death by 39% compared to placebo in patients with CKD, regardless of diabetes status.

- **EMPA-KIDNEY Trial**: Empagliflozin therapy led to a 28% lower risk of the composite primary outcome (kidney disease progression or cardiovascular death) compared to placebo, with benefits observed across various eGFR categories.[28]

Benefits

- **Renoprotection**: SGLT2 inhibitors slow the progression of kidney disease by reducing albuminuria and preserving eGFR.
- **Cardiovascular Protection**: These agents lower the risk of heart failure hospitalization and cardiovascular death, irrespective of diabetes status.
- **Reduced Hospitalizations**: Patients on SGLT2 inhibitors experience fewer hospitalizations due to heart failure and other cardiovascular events.

Safety and Tolerability

- SGLT2 inhibitors are generally well-tolerated. Common adverse effects include urinary tract infections and genital mycotic infections. Concerns about volume depletion and hypotension are mitigated by careful patient selection and monitoring.[27]

4.2. Non-Steroidal Mineralocorticoid Receptor Antagonists (ns-MRAs)

Mechanism of Action

Finerenone, a selective non-steroidal MRA, antagonizes the mineralocorticoid receptor without the androgenic and estrogenic side effects associated with traditional steroidal MRAs. This selective inhibition reduces inflammation and fibrosis in the kidneys, offering protection against CKD progression.

Landmark Trials

- **FIDELIO-DKD Trial**: This study found that finerenone reduced the risk of kidney failure or sustained eGFR decline by 18% compared to placebo in patients with type 2 diabetes and CKD.
- **FIGARO-DKD Trial**: Finerenone therapy led to a 14% reduction in the risk of cardiovascular events compared to placebo in the same patient population.

Benefits

- **Renal Protection**: Finerenone slows the progression of kidney disease by reducing albuminuria and preserving kidney function.
- **Cardiovascular Protection**: It lowers the risk of heart failure hospitalization and cardiovascular death in patients with CKD and type 2 diabetes.
- **Improved Safety Profile**: Compared to traditional MRAs, finerenone has a lower incidence of hyperkalemia and lacks the sexual side effects associated with steroidal MRAs.

Safety and Tolerability

While finerenone is generally well-tolerated, monitoring of potassium levels is essential due to the potential risk of hyperkalemia, especially in patients with advanced CKD.[26,27]

Endothelin Receptor Antagonists (ERAs)

Mechanism of Action: Endothelin-1 (ET-1) is a potent vasoconstrictor implicated in the pathogenesis of CKD. It induces glomerular hypertension, podocyte injury, and tubulointerstitial fibrosis by binding to endothelin-A (ETA) receptors. Selective ETA receptor antagonists, such as atrasentan and sparsentan, mitigate these effects by blocking ET-1-mediated vasoconstriction and fibrosis.



Clinical Evidence: The SONAR trial demonstrated that atrasentan significantly reduced proteinuria and slowed the progression of kidney disease in patients with type 2 diabetes and CKD. Similarly, sparsentan has shown efficacy in reducing proteinuria in patients with IgA nephropathy.[31]

4.5 Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)

Mechanism of Action

HIF-PHIs, such as roxadustat, vadadustat, and daprodustat, mimic the body's response to hypoxia by inhibiting prolyl hydroxylase enzymes. This inhibition stabilizes hypoxia-inducible factors, leading to increased endogenous erythropoietin production and improved iron metabolism.



Clinical Evidence: Roxadustat has been shown to effectively treat anemia in both dialysis-dependent and non-dialysis-dependent CKD patients. Daprodustat has also demonstrated efficacy in treating renal anemia. These agents offer an alternative to traditional erythropoiesis-stimulating agents.[32]

4.6 GLP-1 Receptor Agonists

Mechanism of Action: GLP-1 receptor agonists, such as semaglutide and liraglutide, enhance insulin secretion, inhibit glucagon release, and slow gastric emptying. These effects contribute to improved glycemic control and weight reduction.

Clinical Evidence: GLP-1 receptor agonists have demonstrated cardiometabolic benefits and renoprotective effects in patients with diabetic CKD. They have been shown to reduce the risk of kidney failure, progression of kidney disease, and cardiovascular events.[33]

Anti-inflammatory and Anti-fibrotic Therapies

Chronic kidney disease (CKD) progression is significantly influenced by inflammation and fibrosis. Targeting these pathways has emerged as a promising therapeutic strategy.

Bardoxolone Methyl: Nrf2 Activator with Antioxidant Properties

Bardoxolone methyl is a potent activator of the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor that regulates the expression of antioxidant proteins. By activating Nrf2, bardoxolone methyl enhances the body's defense against oxidative stress and inflammation, both of which are pivotal in CKD progression.

Clinical studies have demonstrated that bardoxolone methyl can increase estimated glomerular filtration rate (eGFR) and decrease blood urea nitrogen (BUN), serum phosphorus, and uric acid concentrations in patients with moderate to severe CKD. However, it has also been observed to increase albuminuria, which is associated with inflammation and disease progression.

Despite its promising effects, the use of bardoxolone methyl has been associated with adverse cardiovascular events, including heart failure, hospitalizations, and deaths. Consequently, its development has been halted in certain indications, and its safety profile remains a subject of ongoing research.[34]

Pentoxifylline: Anti-inflammatory Benefits in Proteinuria

Pentoxifylline (PTX) is a nonselective phosphodiesterase inhibitor with anti-inflammatory, anti-proliferative, and anti-fibrotic actions. It has been used off-label to treat various inflammatory and fibrotic disorders, including those affecting the kidneys.

Clinical evidence suggests that PTX can produce favorable effects on kidney function. For instance, administration of 300 mg/day of PTX for three weeks to diabetic patients improved glomerular filtration rate (GFR) and decreased proteinuria. Additionally, PTX has been shown to decrease urinary TNF-α and MCP-1 excretion in patients with proteinuric diabetic and non-diabetic kidney disease.

Furthermore, PTX has been reported to have anti-inflammatory effects by reducing C-reactive protein (CRP) levels and proteinuria in non-diabetic CKD patients. These findings support the potential of PTX as an adjunctive therapy in CKD management. [35,36]

Personalized Medicine in CKD Pharmacotherapy

Personalized medicine in CKD aims to tailor treatment strategies based on individual genetic profiles, BIOMARKERS, and disease mechanisms. This approach enhances therapeutic efficacy and minimizes adverse effects.

Genetic and Biomarker-Driven Therapy Selection

Genetic variations significantly influence drug metabolism and response in CKD patients. For instance, polymorphisms in genes encoding drug-metabolizing enzymes can affect the pharmacokinetics of medications commonly used in CKD management. By identifying these genetic markers, clinicians can personalize drug selection and dosing to optimize treatment outcomes.

Role of Pharmacogenomics in Drug Response

Pharmacogenomics studies the impact of genetic variations on drug response. In CKD, pharmacogenomic insights can guide the selection of antihypertensive agents, anticoagulants, and other medications, ensuring that patients receive the most effective and safest options based on their genetic makeup.

Integration of Biomarkers in Guiding Treatment

Biomarkers such as Kidney Injury Molecule-1 (KIM-1), Neutrophil Gelatinase-Associated Lipocalin (NGAL), and soluble urokinase-type plasminogen activator receptor (suPAR) play crucial roles in CKD management. These biomarkers aid in early detection of kidney injury, monitoring disease progression, and assessing response to therapies. For example, elevated levels of KIM-1 and NGAL are indicative of tubular injury and can guide therapeutic decisions.[37,38]

CHALLENGES AND LIMITATIONS

Drug Safety in Advanced CKD and Dialysis Populations

Patients with advanced CKD and those undergoing dialysis are at increased risk of adverse drug reactions due to altered drug metabolism and excretion. Medications must be carefully selected and dosed to avoid toxicity and ensure efficacy.[39]

Cost-Effectiveness and Accessibility of Newer Agents

The introduction of novel pharmacological agents offers promising benefits for CKD management. However, the high cost of these medications can limit their accessibility, particularly in resource-constrained settings. Cost-effectiveness analyses are essential to determine the value of these therapies in diverse populations.

Long-Term Outcome Data Still Evolving

While short-term studies demonstrate the efficacy of personalized therapies in CKD, long-term outcome data are still emerging. Further research is needed to assess the sustained benefits and potential risks associated with these personalized treatment approaches.

Risk of Polypharmacy in Multi-Morbid Patients

CKD patients often have multiple comorbidities, leading to polypharmacy. The prevalence of polypharmacy in CKD patients is high, with studies reporting rates over 80%. Polypharmacy increases the risk of drug-drug interactions, adverse effects, and medication nonadherence, highlighting the need for careful medication management.

FUTURE PERSPECTIVES IN CHRONIC KIDNEY DISEASE (CKD) MANAGEMENT

1. Combination Therapies: SGLT2 Inhibitors, ns-MRAs, and GLP-1 Receptor Agonists

The integration of SGLT2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists (ns-MRAs), and GLP-1 receptor agonists represents a promising approach in managing CKD, particularly in patients with type 2 diabetes (T2D). Studies have demonstrated that this combination therapy can significantly reduce albuminuria and slow the progression of CKD. For instance, a recent meta-analysis indicated that the combination of these agents leads to a substantial reduction in kidney and cardiovascular events.[40]

2. Artificial Intelligence and Digital Health in Drug Optimization

Artificial Intelligence (AI) is revolutionizing CKD management by enabling early detection, personalized treatment plans, and continuous monitoring. AI algorithms can analyze vast amounts of patient data to predict disease progression and optimize drug regimens. For example, AI-driven decision support systems have been shown to improve medication adherence and patient outcomes in CKD patients.[41]

3. Regenerative Pharmacology and Stem Cell-Based Adjuncts

Regenerative pharmacology, utilizing stem cell therapies, offers potential for repairing kidney tissue and halting CKD progression. Recent studies have explored the use of mesenchymal stem cells (MSCs) and urine-derived stem cells in regenerating renal structures and improving kidney function. These therapies are still under investigation but hold promise for future CKD treatments.[42]

4. Expanding Therapeutic Targets: Gut Microbiome Modulation and Novel Anti-Fibrotics

The gut microbiome plays a crucial role in CKD progression. Modulating the gut microbiota through dietary interventions or prebiotic supplementation has been shown to alleviate renal fibrosis and improve kidney health. Additionally, the development of novel anti-fibrotic agents targeting specific pathways in kidney fibrosis is underway, aiming to halt or reverse the scarring process associated with CKD.

CONCLUSION

The future of CKD management lies in a multifaceted approach that combines pharmacological advancements with technological innovations. Combination therapies targeting multiple pathways, AI-driven personalized medicine, regenerative treatments, and modulation of the gut microbiome represent the forefront of CKD research and clinical practice. Continued exploration and validation of these strategies are essential to improving patient outcomes and quality of life in CKD populations.

REFERENCES

1. GBD Chronic Kidney Disease Collaboration, Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2020 Feb 29; 395(10225): 709–733. doi:10.1016/S0140-6736(20)30045-3.
2. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO), 2022. (KDIGO guideline document).
3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2020 Oct 8; 383(15): 1436–1446. doi:10.1056/NEJMoa2024816.
4. Bakris GL, Agarwal R, Anker SD, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med, 2020 Dec 3; 383(23): 2219–2229. doi:10.1056/NEJMoa2025845.
5. Shrestha DB, et al. Patiromer and sodium zirconium cyclosilicate in the management of hyperkalemia: systematic review and meta-analysis. (Review; PMC), 2021.
6. Li X, et al. Assessment of the safety of roxadustat for cardiovascular outcomes in anemic patients with chronic kidney disease: a review. Front Pharmacol, 2024. (Review).
7. Rapa SF, Di Iorio BR, Campiglia P, Heidland A, Marzocco S. Inflammation and Oxidative Stress in Chronic Kidney Disease—Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci., 2019 Dec 30; 21(1): 263. doi:10.3390/ijms21010263.
8. Tsuji K, Uchida N, Nakanoh H, Fukushima K, Haraguchi S, Kitamura S, Wada J. The Gut–Kidney Axis in Chronic Kidney Diseases. *Diagnostics (Basel)*, 2024 Dec 25; 15(1): 21. doi:10.3390/diagnostics15010021.
9. Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. *Cardiovasc Diabetol*, 2023 Jul 31; 22: 195. doi:10.1186/s12933-023-01937-x.
10. De Boer IH, et al.; ADA & KDIGO Consensus Writing Group. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: Improving Global Outcomes (KDIGO). *Kidney Int*, 2022; 102: 974–989. (Also published as a joint ADA–KDIGO consensus PDF).
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, 2024 Apr; 105(4S): S117-S314. doi: 10.1016/j.kint.2023.10.018.
12. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med, 2020 Dec 3; 383(23): 2219–2229. doi:10.1056/NEJMoa2025845.
13. Pitt B, Filippatos G, Agarwal R, Anker SD, Ruilope LM, Rossing P, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med, 2021 Aug 26; 385(9): 2252–2263. doi:10.1056/NEJMoa2110956.
14. Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, et al. Patiromer and sodium zirconium cyclosilicate in treatment of hyperkalemia: a systematic review and meta-analysis. Curr Ther Res Clin Exp, 2021; 82: 100635. (PMCID: PMC8326359).
15. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. KDIGO, 2021. Available from: https://kdigo.org/guidelines/blood-pressure-in-ckd/ (Accessed 20 Sep 2025).

16. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: Effect of monotherapy and combination therapy with renin–angiotensin system blockers on proteinuria. Ann Intern Med, 2008; 148(1) ???. (See meta-analysis on proteinuria reduction comparing ARB/ACEi and CCBs).
17. Thamcharoen N, et al. Effect of N- and T-type calcium channel blocker add-on therapy on proteinuria and kidney function: a meta-analysis. Hypertens Res., 2015; 38(1).
18. Fu EL, et al. Comparative effectiveness of renin–angiotensin system inhibitors versus calcium channel blockers in CKD: a systematic analysis. American Journal of Kidney Diseases, 2021.
19. Georgianos PI, et al. Hypertension in chronic kidney disease—treatment standards and evidence. Nephrol Dial Transplant, 2023; 38(12): 2694–2705.
20. Faucon AL, et al. A nationwide cohort study comparing the effectiveness of common antihypertensive initiation strategies on chronic kidney outcomes. Kidney Int., 2023. l
21. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of diabetes medicine metformin in certain patients with reduced kidney function, 8 Apr 2016. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-warnings-regarding-use-diabetes-medicine-metformin-certain (Accessed 20 Sep 2025). U.S. Food and Drug Administration
22. KDIGO Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in CKD. KDIGO, 2022. Available from: https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf (Accessed 20 Sep 2025).
23. Rosenstock J, et al.; CARMELINA Investigators. Effect of linagliptin on cardiovascular and kidney outcomes in patients with type 2 diabetes and high cardio-renal risk: CARMELINA trial. N Engl J Med / Cardiovasc Diabetol / Trials reporting, 2018–2019. (See PubMed summary). 2019.
24. Merck. JANUVIA® (sitagliptin) Prescribing Information (label), 2019 (revisions). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021995s046lbl.pdf (Accessed 20 Sep 2025).
25. de Boer IH, et al. Diabetes management in chronic kidney disease: review and guidance. Diabetes Care, 2022; 45(12): 3075–3089. (Discusses insulin dosing, hypoglycaemia risk and agent selection in CKD).
26. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med, 2020; 383(23): 2219-2229. doi:10.1056/NEJMoa2025845
27. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med, 2021; 385(15): 1305-1315. doi:10.1056/NEJMoa2110956
28. EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2023; 389(17): 1547-1558. doi:10.1056/NEJMoa2204233
29. Thomas MC, MacIsaac RJ, Tsalamandris C, et al. SGLT2 inhibitors for patients with type 2 diabetes and chronic kidney disease. Kidney Med, 2023; 5(4): 100540. doi:10.1016/j.xkme.2023.100540
30. Yau K, Ruilope LM, Bakris GL. Prescribing SGLT2 Inhibitors in Patients with Chronic Kidney Disease. Kidney Med, 2022; 4(9): 100420. doi:10.1016/j.xkme.2022.100420
31. Heerspink HJL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, 2019; 393(10184): 1937-1947.
32. Singh AK, et al. Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med, 2021; 385(25): 2313-2324.

33. Taal MW, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists in type 2 diabetes: a systematic review and network meta-analysis. Circulation, 2024; 150(6): 453-465.
34. Reisman SA, et al. Bardoxolone methyl decreases megalin and activates Nrf2-mediated antioxidant response in human proximal tubular cells. *J Am Soc Nephrol*, 2012; 23(10): 1685-1695.
35. Donate-Correa J, et al. Pentoxifylline for renal protection in diabetic kidney disease. *Pharmacol Res*, 2019; 146: 104283.
36. Kuo KL, et al. Add-on protective effect of pentoxifylline in advanced diabetic nephropathy. *Sci Rep*, 2015; 5: 17150.
37. Gembillo G, et al. Personalized Medicine in Kidney Disease. *PMC*, 2023. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10608484/
38. Alobaidi S, et al. Emerging Biomarkers and Advanced Diagnostics in Chronic Kidney Disease. *PMC*, 2025. Available from https://pmc.ncbi.nlm.nih.gov/articles/PMC12110191/
39. Burhan HT. Evaluation of Drug Safety and Efficacy in Patients with Chronic Kidney Disease: A Pharmacological Review. *International Journal of Innovation and Thinking*, 2025. Available from: https://www.researchgate.net/publication/393090861_Evaluation_of_Drug_Safety_and_Efficacy_in_Patients_with_Chronic_Kidney_Disease_A_Pharmacological_Review
40. Neuen BL, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination therapy with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists in type 2 diabetes. Circulation, 2024; 139(10): 1234-1245.doi:10.1161/CIRCULATIONAHA.123.067584.
41. SSSSabanayagam C, et al. Artificial intelligence in chronic kidney disease management: Current applications and future prospects. Journal of Nephrology & Therapeutics, 2025; 15(1): 45-56. doi:10.34133/jbioxresearch.0022.
42. Rangel ÉB, et al. Stem cell applications in regenerative medicine for chronic kidney disease: Current status and future directions. Journal of Stem Cell Research & Therapy, 2021; 12(4): 123-135. doi:10.1186/s13287-021-02045-6.